{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:03:33Z","timestamp":1785323013302,"version":"3.55.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,29]]},"DOI":"10.7759\/cureus.113572","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:28:57Z","timestamp":1785320937000},"source":"Crossref","is-referenced-by-count":0,"title":["Montelukast and Bilastine Combination Therapy in Allergic Rhinitis: A Narrative Review of Evidence"],"prefix":"10.7759","author":[{"given":"Surinder","family":"Jindal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed N","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketaki","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitanya","family":"Bhargave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintan","family":"Khandhedia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyog","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00227-0","article-title":"Allergic rhinitis","volume":"6","author":"Bousquet J","year":"2020","unstructured":"Bousquet J, Anto JM, Bachert C, et al.. Allergic rhinitis. Nat Rev Dis Primers. 2020, 6:95. 10.1038\/s41572-020-00227-0","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(11)60130-X","article-title":"Allergic rhinitis","volume":"378","author":"Greiner AN","year":"2011","unstructured":"Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011, 378:2112-2122.","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.874114","article-title":"Allergic rhinitis: a clinical and pathophysiological overview","volume":"9","author":"Nur Husna SM","year":"2022","unstructured":"Nur Husna SM, Tan HT, Md Shukri N, Mohd Ashari NS, Wong KK. Allergic rhinitis: a clinical and pathophysiological overview. Front Med (Lausanne). 2022, 9:874114. 10.3389\/fmed.2022.874114","journal-title":"Front Med (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision","volume":"140","author":"Bro\u017cek JL","year":"2017","unstructured":"Bro\u017cek JL, Bousquet J, Agache I, et al.. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017, 140:950-8. 10.1016\/j.jaci.2017.03.050","journal-title":"J Allergy Clin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12157","article-title":"House dust mite sensitization is the main risk factor for the increase in prevalence of wheeze in 13- to 14-year-old schoolchildren in Guangzhou city, China","volume":"43","author":"Li J","year":"2013","unstructured":"Li J, Wang H, Chen Y, Zheng J, Wong GW, Zhong N. House dust mite sensitization is the main risk factor for the increase in prevalence of wheeze in 13- to 14-year-old schoolchildren in Guangzhou city, China. Clin Exp Allergy. 2013, 43:1171-9. 10.1111\/cea.12157","journal-title":"Clin Exp Allergy"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1412282","article-title":"Allergic rhinitis","volume":"372","author":"Wheatley LM","year":"2015","unstructured":"Wheatley LM, Togias A. Allergic rhinitis. N Engl J Med. 2015, 372:456-63. 10.1056\/NEJMcp1412282","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-016-0673-z","article-title":"The epidemiologic characteristics of healthcare provider-diagnosed eczema, asthma, allergic rhinitis, and food allergy in children: a retrospective cohort study","volume":"16","author":"Hill DA","year":"2016","unstructured":"Hill DA, Grundmeier RW, Ram G, Spergel JM. The epidemiologic characteristics of healthcare provider-diagnosed eczema, asthma, allergic rhinitis, and food allergy in children: a retrospective cohort study. BMC Pediatr. 2016, 16:133. 10.1186\/s12887-016-0673-z","journal-title":"BMC Pediatr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14295","article-title":"Allergic rhinitis in India","volume":"53","author":"Moitra S","year":"2023","unstructured":"Moitra S, Mahesh PA, Moitra S. Allergic rhinitis in India. Clin Exp Allergy. 2023, 53:765-76. 10.1111\/cea.14295","journal-title":"Clin Exp Allergy"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.648263","article-title":"Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review","volume":"28","author":"Bousquet J","year":"2012","unstructured":"Bousquet J, Ans\u00f3tegui I, Canonica GW, et al.. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012, 28:131-9. 10.1185\/03007995.2011.648263","journal-title":"Curr Med Res Opin"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2011.1.3.157","article-title":"Overview on the pathomechanisms of allergic rhinitis","volume":"1","author":"Pawankar R","year":"2011","unstructured":"Pawankar R, Mori S, Ozu C, Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allergy. 2011, 1:157-67. 10.5415\/apallergy.2011.1.3.157","journal-title":"Asia Pac Allergy"},{"key":"ref11","article-title":"Role of leukotriene antagonists and antihistamines in treatment of allergic rhinitis and asthma comorbidity","volume":"3","author":"Ba\u00e7\u00e7\u0131o\u011fu A","year":"2013","unstructured":"Ba\u00e7\u00e7\u0131o\u011fu A, Yorganc\u0131o\u011flu A, Cingi C, \u00c7uhadaro\u011flu \u00c7. Role of leukotriene antagonists and antihistamines in treatment of allergic rhinitis and asthma comorbidity. ENT Updates. 2013, 3:34-39.","journal-title":"ENT Updates"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.004184","article-title":"International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions","volume":"63","author":"B\u00e4ck M","year":"2011","unstructured":"B\u00e4ck M, Dahl\u00e9n SE, Drazen JM, et al.. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev. 2011, 63:539-84. 10.1124\/pr.110.004184","journal-title":"Pharmacol Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.600689","article-title":"Montelukast for the treatment of asthma in the adult population","volume":"12","author":"Amlani S","year":"2011","unstructured":"Amlani S, Nadarajah T, McIvor RA. Montelukast for the treatment of asthma in the adult population. Expert Opin Pharmacother. 2011, 12:2119-28. 10.1517\/14656566.2011.600689","journal-title":"Expert Opin Pharmacother"},{"key":"ref14","unstructured":"U.S. Food & Drug Administration. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. Risks may include suicidal thoughts or actions. (2020). https.\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-boxed-warning-about-serious-mental-health-side-ef...."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2025.17.6.692","article-title":"Efficacy of a combination therapy of montelukast and antihistamines in allergic rhinitis: a systematic review and network meta-analysis","volume":"17","author":"Kim JS","year":"2025","unstructured":"Kim JS, Stybayeva G, Hwang SH. Efficacy of a combination therapy of montelukast and antihistamines in allergic rhinitis: a systematic review and network meta-analysis. Allergy Asthma Immunol Res. 2025, 17:692-708. 10.4168\/aair.2025.17.6.692","journal-title":"Allergy Asthma Immunol Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.03.023","article-title":"Current management of allergic rhinitis","volume":"12","author":"Klimek L","year":"2024","unstructured":"Klimek L, Mullol J, Ellis AK, et al.. Current management of allergic rhinitis. J Allergy Clin Immunol Pract. 2024, 12:1399-412. 10.1016\/j.jaip.2024.03.023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/all.70131","article-title":"Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI guidelines-2024-2025 revision: part I-guidelines on intranasal treatments","volume":"81","author":"Sousa-Pinto B","year":"2026","unstructured":"Sousa-Pinto B, Bousquet J, Vieira RJ, et al.. Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI guidelines-2024-2025 revision: part I-guidelines on intranasal treatments. Allergy. 2026, 81:954-76. 10.1111\/all.70131","journal-title":"Allergy"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.21.2581","article-title":"Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis","volume":"161","author":"Kaszuba SM","year":"2001","unstructured":"Kaszuba SM, Baroody FM, deTineo M, Haney L, Blair C, Naclerio RM. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med. 2001, 161:2581-7. 10.1001\/archinte.161.21.2581","journal-title":"Arch Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12130","article-title":"Worldwide prevalence of rhinitis in adults: a review of definitions and temporal evolution","volume":"12","author":"Savour\u00e9 M","year":"2022","unstructured":"Savour\u00e9 M, Bousquet J, Jaakkola JJ, Jaakkola MS, Jacquemin B, Nadif R. Worldwide prevalence of rhinitis in adults: a review of definitions and temporal evolution. Clin Transl Allergy. 2022, 12:e12130. 10.1002\/clt2.12130","journal-title":"Clin Transl Allergy"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.007","article-title":"Rhinitis 2020: a\u00a0practice parameter update","volume":"146","author":"Dykewicz MS","year":"2020","unstructured":"Dykewicz MS, Wallace DV, Amrol DJ, et al.. Rhinitis 2020: a\u00a0practice parameter update. J Allergy Clin Immunol. 2020, 146:721-67. 10.1016\/j.jaci.2020.07.007","journal-title":"J Allergy Clin Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.09.002","article-title":"Impact of rhinitis on work productivity: a systematic review","volume":"6","author":"Vandenplas O","year":"2018","unstructured":"Vandenplas O, Vinnikov D, Blanc PD, et al.. Impact of rhinitis on work productivity: a systematic review. J Allergy Clin Immunol Pract. 2018, 6:1274-1286.e9. 10.1016\/j.jaip.2017.09.002","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)","volume":"63","author":"Bousquet J","year":"2008","unstructured":"Bousquet J, Khaltaev N, Cruz AA, et al.. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008, 63:8-160. 10.1111\/j.1398-9995.2007.01620.x","journal-title":"Allergy"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/all.13200","article-title":"Non-allergic rhinitis: position paper of the European Academy of Allergy and Clinical Immunology","volume":"72","author":"Hellings PW","year":"2017","unstructured":"Hellings PW, Klimek L, Cingi C, et al.. Non-allergic rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017, 72:1657-65. 10.1111\/all.13200","journal-title":"Allergy"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2012.2.2.93","article-title":"Impact of allergic rhinitis in school going children","volume":"2","author":"Panjabi C","year":"2012","unstructured":"Panjabi C, Mir E, Shah A. Impact of allergic rhinitis in school going children. Asia Pac Allergy. 2012, 2:93-100. 10.5415\/apallergy.2012.2.2.93","journal-title":"Asia Pac Allergy"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3345\/cep.2020.00822","article-title":"Prevalence, comorbidities, diagnosis, and treatment of nonallergic rhinitis: real-world comparison with allergic rhinitis","volume":"64","author":"Yum HY","year":"2021","unstructured":"Yum HY, Ha EK, Shin YH, Han MY. Prevalence, comorbidities, diagnosis, and treatment of nonallergic rhinitis: real-world comparison with allergic rhinitis. Clin Exp Pediatr. 2021, 64:373-83. 10.3345\/cep.2020.00822","journal-title":"Clin Exp Pediatr"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(20)30061-9","article-title":"The burden of allergic diseases in the Indian subcontinent: barriers and challenges. The LANCET Global Health","volume":"8","author":"Krishna MT","year":"2020","unstructured":"Krishna MT, Mahesh PA, Vedanthan PK, Mehta V, Moitra S, Christopher DJ. The burden of allergic diseases in the Indian subcontinent: barriers and challenges. The LANCET Global Health. Lancet Global Health. 2020, 8:478-479.","journal-title":"Lancet Global Health"},{"key":"ref27","article-title":"Differentiation between allergic and non-allergic rhinitis in children with chronic rhinitis, Allergy clinic, Phramongkutklao Hospital","volume":"6","author":"Songchitsomboon T","year":"2022","unstructured":"Songchitsomboon T, Sirisungreung A, Suksawat Y. Differentiation between allergic and non-allergic rhinitis in children with chronic rhinitis, Allergy clinic, Phramongkutklao Hospital. J SouthEast Asian Med Res. 2022, 6:e0125.","journal-title":"J SouthEast Asian Med Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00943-2022","article-title":"Rhinitis phenotypes and multimorbidities in the general population: the CONSTANCES cohort","volume":"61","author":"Savour\u00e9 M","year":"2023","unstructured":"Savour\u00e9 M, Bousquet J, Leynaert B, et al.. Rhinitis phenotypes and multimorbidities in the general population: the CONSTANCES cohort. Eur Respir J. 2023, 61:2200943. 10.1183\/13993003.00943-2022","journal-title":"Eur Respir J"},{"key":"ref29","article-title":"Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations","volume":"61","author":"Meltzer EO","year":"2012","unstructured":"Meltzer EO, Gross GN, Katial R, Storms WW. Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations. J Fam Pract. 2012, 61:5-10.","journal-title":"J Fam Pract"},{"key":"ref30","article-title":"Clinical manifestations of allergic rhinitis","volume":"5","author":"Lakhani N","year":"2012","unstructured":"Lakhani N, North M, Ellis AK. Clinical manifestations of allergic rhinitis. J Aller Ther. 2012, 5:1-5.","journal-title":"J Aller Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ai.2018.03.002","article-title":"Molecular aspects of allergens and allergy","volume":"138","author":"Valenta R","year":"2018","unstructured":"Valenta R, Karaulov A, Niederberger V, et al.. Molecular aspects of allergens and allergy. Adv Immunol. 2018, 138:195-256. 10.1016\/bs.ai.2018.03.002","journal-title":"Adv Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/all.13356","article-title":"Quality of life is significantly impaired in nonallergic rhinitis patients","volume":"73","author":"Segboer CL","year":"2018","unstructured":"Segboer CL, Terreehorst I, Gevorgyan A, Hellings PW, van Drunen CM, Fokkens WJ. Quality of life is significantly impaired in nonallergic rhinitis patients. Allergy. 2018, 73:1094-100. 10.1111\/all.13356","journal-title":"Allergy"},{"key":"ref33","article-title":"Allergic rhinitis","author":"Akhouri S","year":"2026","unstructured":"Akhouri S, House SA. Allergic rhinitis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s12070-015-0828-5","article-title":"Allergic rhinitis: an overview","volume":"67","author":"Varshney J","year":"2015","unstructured":"Varshney J, Varshney H. Allergic rhinitis: an overview. Indian J Otolaryngol Head Neck Surg. 2015, 67:143-9. 10.1007\/s12070-015-0828-5","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"ref35","article-title":"Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - the ADRIAL cohort study","volume":"48","author":"del Cuvillo A","year":"2010","unstructured":"del Cuvillo A, Montoro J, Bartra J, et al.. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - the ADRIAL cohort study. Rhinology. 2010, 48:201-5.","journal-title":"Rhinology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2023.15.2.145","article-title":"KAAACI allergic rhinitis guidelines: part 2. Update in non-pharmacological management","volume":"15","author":"Park DY","year":"2023","unstructured":"Park DY, Lee YJ, Kim DK, et al.. KAAACI allergic rhinitis guidelines: part 2. Update in non-pharmacological management. Allergy Asthma Immunol Res. 2023, 15:145-59. 10.4168\/aair.2023.15.2.145","journal-title":"Allergy Asthma Immunol Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.05.014","article-title":"Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"66","author":"Okubo K","year":"2017","unstructured":"Okubo K, Gotoh M, Asako M, et al.. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergol Int. 2017, 66:97-105. 10.1016\/j.alit.2016.05.014","journal-title":"Allergol Int"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/0194599814562166","article-title":"Clinical practice guideline. Allergic rhinitis executive summary","volume":"152","author":"Seidman MD","year":"2015","unstructured":"Seidman MD, Gurgel RK, Lin SY, et al.. Clinical practice guideline. Allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015, 152:197-206. 10.1177\/0194599814562166","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2018.10.4.300","article-title":"Chinese Society of Allergy guidelines for diagnosis and treatment of allergic rhinitis","volume":"10","author":"Cheng L","year":"2018","unstructured":"Cheng L, Chen J, Fu Q, et al.. Chinese Society of Allergy guidelines for diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res. 2018, 10:300-53. 10.4168\/aair.2018.10.4.300","journal-title":"Allergy Asthma Immunol Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12953","article-title":"BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007)","volume":"47","author":"Scadding GK","year":"2017","unstructured":"Scadding GK, Kariyawasam HH, Scadding G, et al.. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2017, 47:856-89. 10.1111\/cea.12953","journal-title":"Clin Exp Allergy"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23090","article-title":"International consensus statement on allergy and rhinology: allergic rhinitis - 2023","volume":"13","author":"Wise SK","year":"2023","unstructured":"Wise SK, Damask C, Roland LT, et al.. International consensus statement on allergy and rhinology: allergic rhinitis - 2023. Int Forum Allergy Rhinol. 2023, 13:293-859. 10.1002\/alr.23090","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.10.006","article-title":"Management of allergic rhinitis: a review for the community pharmacist","volume":"39","author":"May JR","year":"2017","unstructured":"May JR, Dolen WK. Management of allergic rhinitis: a review for the community pharmacist. Clin Ther. 2017, 39:2410-9. 10.1016\/j.clinthera.2017.10.006","journal-title":"Clin Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2003.00468.x","article-title":"ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy","volume":"59","author":"Bousquet J","year":"2004","unstructured":"Bousquet J, Cauwenberge PV, Khaltaev N. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergy. 2004, 59:373-87. 10.1111\/j.1398-9995.2003.00468.x","journal-title":"Allergy"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-020-00436-y","article-title":"Towards definitive management of allergic rhinitis: best use of new and established therapies","volume":"16","author":"Hossenbaccus L","year":"2020","unstructured":"Hossenbaccus L, Linton S, Garvey S, Ellis AK. Towards definitive management of allergic rhinitis: best use of new and established therapies. Allergy Asthma Clin Immunol. 2020, 16:39. 10.1186\/s13223-020-00436-y","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2023.1217388","article-title":"Mechanism and clinical evidence of immunotherapy in allergic rhinitis","volume":"4","author":"De Carli M","year":"2023","unstructured":"De Carli M, Capezzali E, Tonon S, Frossi B. Mechanism and clinical evidence of immunotherapy in allergic rhinitis. Front Allergy. 2023, 4:1217388. 10.3389\/falgy.2023.1217388","journal-title":"Front Allergy"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2046731","article-title":"Safety of intranasal corticosteroids for allergic rhinitis in children","volume":"21","author":"Zhang M","year":"2022","unstructured":"Zhang M, Ni JZ, Cheng L. Safety of intranasal corticosteroids for allergic rhinitis in children. Expert Opin Drug Saf. 2022, 21:931-8. 10.1080\/14740338.2022.2046731","journal-title":"Expert Opin Drug Saf"},{"key":"ref47","article-title":"Montelukast","author":"Wermuth HR","year":"2026","unstructured":"Wermuth HR, Badri T, Takov V. Montelukast. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108412","article-title":"Levocetirizine and montelukast in the COVID-19 treatment paradigm","volume":"103","author":"May BC","year":"2022","unstructured":"May BC, Gallivan KH. Levocetirizine and montelukast in the COVID-19 treatment paradigm. Int Immunopharmacol. 2022, 103:108412. 10.1016\/j.intimp.2021.108412","journal-title":"Int Immunopharmacol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/608930","article-title":"Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function","volume":"2014","author":"Theron AJ","year":"2014","unstructured":"Theron AJ, Steel HC, Tintinger GR, Gravett CM, Anderson R, Feldman C. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res. 2014, 2014:608930. 10.1155\/2014\/608930","journal-title":"J Immunol Res"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1177\/19458924221086268","article-title":"A comparative study of montelukast and azelastine add on therapy in moderate to severe allergic rhinitis treatment: a double-blind randomized clinical trial","volume":"36","author":"Esmaeilzadeh H","year":"2022","unstructured":"Esmaeilzadeh H, Far NM, Nabavizadeh SH, Babaeian M, Hadipour M, Alyasin S. A comparative study of montelukast and azelastine add on therapy in moderate to severe allergic rhinitis treatment: a double-blind randomized clinical trial. Am J Rhinol Allergy. 2022, 36:559-67. 10.1177\/19458924221086268","journal-title":"Am J Rhinol Allergy"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.04.021","article-title":"A randomized, multicenter, double-blind, phase III study to evaluate the efficacy on allergic rhinitis and safety of a combination therapy of montelukast and levocetirizine in patients with asthma and allergic rhinitis","volume":"40","author":"Kim MK","year":"2018","unstructured":"Kim MK, Lee SY, Park HS, et al.. A randomized, multicenter, double-blind, phase III study to evaluate the efficacy on allergic rhinitis and safety of a combination therapy of montelukast and levocetirizine in patients with asthma and allergic rhinitis. Clin Ther. 2018, 40:1096-1107.e1. 10.1016\/j.clinthera.2018.04.021","journal-title":"Clin Ther"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-20-1989","article-title":"A multicenter, prospective, observational study on montelukast monotherapy or montelukast-based combinations treating cough variant asthma","volume":"12","author":"Lin J","year":"2020","unstructured":"Lin J, Wang Z, Qiu C, et al.. A multicenter, prospective, observational study on montelukast monotherapy or montelukast-based combinations treating cough variant asthma. J Thorac Dis. 2020, 12:6573-85. 10.21037\/jtd-20-1989","journal-title":"J Thorac Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.35.3.42","article-title":"Effectiveness and quality of life with montelukast in asthma - a double-blind randomized control trial","volume":"35","author":"Baig MS","year":"2019","unstructured":"Baig MS, Khan RA, Khan K, Rizvi N. Effectiveness and quality of life with montelukast in asthma - a double-blind randomized control trial. Pak J Med Sci. 2019, 35:731-6. 10.12669\/pjms.35.3.42","journal-title":"Pak J Med Sci"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01094","article-title":"Montelukast improves symptoms and lung function in asthmatic women compared with men","volume":"10","author":"Esposito R","year":"2019","unstructured":"Esposito R, Spaziano G, Giannattasio D, et al.. Montelukast improves symptoms and lung function in asthmatic women compared with men. Front Pharmacol. 2019, 10:1094. 10.3389\/fphar.2019.01094","journal-title":"Front Pharmacol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24176","article-title":"Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: a systematic review","volume":"53","author":"Castro-Rodriguez JA","year":"2018","unstructured":"Castro-Rodriguez JA, Rodriguez-Martinez CE, Ducharme FM. Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: a systematic review. Pediatr Pulmonol. 2018, 53:1670-7. 10.1002\/ppul.24176","journal-title":"Pediatr Pulmonol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.08.007","article-title":"The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma","volume":"103","author":"Fritscher LG","year":"2009","unstructured":"Fritscher LG, Rodrigues MT, Zamel N, Chapman KR. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respir Med. 2009, 103:296-300. 10.1016\/j.rmed.2008.08.007","journal-title":"Respir Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2006.08.003","article-title":"A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma","volume":"20","author":"Stelmach I","year":"2007","unstructured":"Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. Pulm Pharmacol Ther. 2007, 20:691-700. 10.1016\/j.pupt.2006.08.003","journal-title":"Pulm Pharmacol Ther"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.097741","article-title":"British guideline on the management of asthma","volume":"63","author":"British Thoracic Society Scottish Intercollegiate Guidelines Network","year":"2008","unstructured":"British Thoracic Society Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2008, 63:iv1-121. 10.1136\/thx.2008.097741","journal-title":"Thorax"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-015-0008-x","article-title":"Bilastine: new insight into antihistamine treatment","volume":"13","author":"Ridolo E","year":"2015","unstructured":"Ridolo E, Montagni M, Bonzano L, Incorvaia C, Canonica GW. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy. 2015, 13:1. 10.1186\/s12948-015-0008-x","journal-title":"Clin Mol Allergy"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S350122","article-title":"A comparative, three-arm, randomized clinical trial to evaluate the effectiveness and tolerability of bilastine vs fexofenadine vs levocetirizine at the standard dose and bilastine vs fexofenadine at higher than the standard dose (up-dosing) vs levocetirizine and hydroxyzine (in combination) in patients with chronic spontaneous urticaria","volume":"15","author":"Shah B","year":"2022","unstructured":"Shah B, Dhoot D, Choudhary A, et al.. A comparative, three-arm, randomized clinical trial to evaluate the effectiveness and tolerability of bilastine vs fexofenadine vs levocetirizine at the standard dose and bilastine vs fexofenadine at higher than the standard dose (up-dosing) vs levocetirizine and hydroxyzine (in combination) in patients with chronic spontaneous urticaria. Clin Cosmet Investig Dermatol. 2022, 15:261-70. 10.2147\/CCID.S350122","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref61","article-title":"Comparative study of bilastine and fexofenadine in control of intermittent allergic rhinitis","volume":"11","author":"Jolly B","year":"2022","unstructured":"Jolly B, Munish KS, Ajith KM, Venkatesha B. Comparative study of bilastine and fexofenadine in control of intermittent allergic rhinitis. Medica Innovatica. 2022, 11:62-68.","journal-title":"Medica Innovatica"},{"key":"ref62","article-title":"Efficacy of oral bilastine in comparison with levocetirizine in allergic rhinitis-a randomised clinical study","volume":"15","author":"Vanitha M","year":"2021","unstructured":"Vanitha M, Sowmini K, Kumari KS, Reddy RN. Efficacy of oral bilastine in comparison with levocetirizine in allergic rhinitis-a randomised clinical study. J Clin Diag Res. 2021, 15:01-04.","journal-title":"J Clin Diag Res"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2023.2209175","article-title":"Efficacy and safety of fixed-dose combination of bilastine-montelukast in adult patients with allergic rhinitis: a phase III, randomized, multi-center, double-blind, active controlled clinical study","volume":"60","author":"Sinha SD","year":"2023","unstructured":"Sinha SD, Perapogu S, Chary S S, et al.. Efficacy and safety of fixed-dose combination of bilastine-montelukast in adult patients with allergic rhinitis: a phase III, randomized, multi-center, double-blind, active controlled clinical study. J Asthma. 2023, 60:2014-20. 10.1080\/02770903.2023.2209175","journal-title":"J Asthma"},{"key":"ref64","article-title":"Comparative analysis of efficacy, safety, and cost-effectiveness of montelukast-bilastine versus montelukast-levocetirizine in paediatric patients with allergic rhinitis","volume":"6","author":"Uppu B","year":"2024","unstructured":"Uppu B, Khaleef SA, Soumya S, Dasari R. Comparative analysis of efficacy, safety, and cost-effectiveness of montelukast-bilastine versus montelukast-levocetirizine in paediatric patients with allergic rhinitis. Int J Acad Med Pharm. 2024, 6:91-95.","journal-title":"Int J Acad Med Pharm"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1021\/acs.est.6b04908","article-title":"Air pollution and climate change effects on allergies in the anthropocene: abundance, interaction, and modification of allergens and adjuvants","volume":"51","author":"Reinmuth-Selzle K","year":"2017","unstructured":"Reinmuth-Selzle K, Kampf CJ, Lucas K, et al.. Air pollution and climate change effects on allergies in the anthropocene: abundance, interaction, and modification of allergens and adjuvants. Environ Sci Technol. 2017, 51:4119-41. 10.1021\/acs.est.6b04908","journal-title":"Environ Sci Technol"},{"key":"ref66","article-title":"Expert opinion on the role of bilastine and bilastine-montelukast combination in the management of allergic rhinitis. An Indian perspective","volume":"11","author":"Jain S","year":"2023","unstructured":"Jain S, Verma S, Balamurugan S, Reddy KR, Christopher DJ. Expert opinion on the role of bilastine and bilastine-montelukast combination in the management of allergic rhinitis. An Indian perspective. J Association Chest Phys. 2023, 11:1-9.","journal-title":"J Association Chest Phys"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20010213","article-title":"Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties","volume":"20","author":"Kawauchi H","year":"2019","unstructured":"Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. Int J Mol Sci. 2019, 20:213. 10.3390\/ijms20010213","journal-title":"Int J Mol Sci"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-5-1","article-title":"Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions","volume":"10","author":"Leceta A","year":"2021","unstructured":"Leceta A, Garc\u00eda A, Sologuren A, Campo C. Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions. Drugs Context. 2021, 10:10.7573\/dic.2021-5-1","journal-title":"Drugs Context"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S105189","article-title":"Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine","volume":"12","author":"Wang XY","year":"2016","unstructured":"Wang XY, Lim-Jurado M, Prepageran N, Tantilipikorn P, Wang DY. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine. Ther Clin Risk Manag. 2016, 12:585-97. 10.2147\/TCRM.S105189","journal-title":"Ther Clin Risk Manag"},{"key":"ref70","article-title":"Prescription trends and patterns for allergic rhinitis treatment in clinical practice","volume":"6","author":"Manjula S","year":"2024","unstructured":"Manjula S, Krishna Kumar M. Prescription trends and patterns for allergic rhinitis treatment in clinical practice. J Otolaryn Allied Sci. 2024, 6:01-05.","journal-title":"J Otolaryn Allied Sci"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55032","article-title":"A perception-based survey on practice patterns pertaining to the diagnosis and management of allergic rhinitis in India","volume":"16","author":"Gupte V","year":"2024","unstructured":"Gupte V, Thakur G, Upadhyaya A, Jain S, Bhargava S. A perception-based survey on practice patterns pertaining to the diagnosis and management of allergic rhinitis in India. Cureus. 2024, 16:e55032. 10.7759\/cureus.55032","journal-title":"Cureus"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-018-0314-1","article-title":"The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option","volume":"15","author":"Bjermer L","year":"2019","unstructured":"Bjermer L, Westman M, Holmstr\u00f6m M, Wickman MC. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. Allergy Asthma Clin Immunol. 2019, 15:24. 10.1186\/s13223-018-0314-1","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-013-0341-4","article-title":"Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis","volume":"13","author":"Cobano\u011flu B","year":"2013","unstructured":"Cobano\u011flu B, Toskala E, Ural A, Cingi C. Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2013, 13:203-8. 10.1007\/s11882-013-0341-4","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1177\/0194599817752624","article-title":"Oral antihistamines alone vs in combination with leukotriene receptor antagonists for allergic rhinitis: a meta-analysis","volume":"158","author":"Liu G","year":"2018","unstructured":"Liu G, Zhou X, Chen J, Liu F. Oral antihistamines alone vs in combination with leukotriene receptor antagonists for allergic rhinitis: a meta-analysis. Otolaryngol Head Neck Surg. 2018, 158:450-8. 10.1177\/0194599817752624","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1111\/all.14007","article-title":"Concomitant bilastine and montelukast as additive therapy for seasonal allergic rhinoconjunctivits and mild-to-moderate asthma. The SKY study","volume":"75","author":"Lavorini F","year":"2020","unstructured":"Lavorini F, Matucci A, Rossi O, Pistolesi M. Concomitant bilastine and montelukast as additive therapy for seasonal allergic rhinoconjunctivits and mild-to-moderate asthma. The SKY study. Allergy. 2020, 75:675-7. 10.1111\/all.14007","journal-title":"Allergy"},{"key":"ref76","article-title":"New SeDEM-ODT expert system for formulation of orodispersible tablets obtained by direct compression","author":"Aguilar JE","year":"2013","unstructured":"Aguilar JE, Montoya EG, Lozano PP, Su\u00f1e Negre JM, Carmona MM, Grau JR. New SeDEM-ODT expert system for formulation of orodispersible tablets obtained by direct compression. Formulation Tools for Pharmaceutical Development. Woodhead Publishing, Sawston, UK; 2013. 137-154."},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.731201","article-title":"Efficacy and safety of bilastine in the treatment of allergic rhinitis: a systematic review and meta-analysis","volume":"12","author":"Randhawa AS","year":"2021","unstructured":"Randhawa AS, Noor NM, Daud MK, Abdullah B. Efficacy and safety of bilastine in the treatment of allergic rhinitis: a systematic review and meta-analysis. Front Pharmacol. 2021, 12:731201. 10.3389\/fphar.2021.731201","journal-title":"Front Pharmacol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1251891","article-title":"Early patient experiences with montelukast orally disintegrating tablets in Japan: a cross-sectional survey of treatment satisfaction in patients with asthma and\/or allergic rhinitis","volume":"33","author":"Whalley D","year":"2017","unstructured":"Whalley D, Petigara T, Rasouliyan L, Tobe K, Tunceli K. Early patient experiences with montelukast orally disintegrating tablets in Japan: a cross-sectional survey of treatment satisfaction in patients with asthma and\/or allergic rhinitis. Curr Med Res Opin. 2017, 33:215-23. 10.1080\/03007995.2016.1251891","journal-title":"Curr Med Res Opin"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.4103\/picr.picr_206_24","article-title":"Effectiveness, safety, and cost-effectiveness of fixed-dose combination of montelukast-bilastine versus montelukast-levocetirizine in allergic rhinitis: a prospective, randomized, open-label, parallel-group study","volume":"16","author":"Dakhale GN","year":"2025","unstructured":"Dakhale GN, Chindhalore CA, Kumar M, Bidkar V. Effectiveness, safety, and cost-effectiveness of fixed-dose combination of montelukast-bilastine versus montelukast-levocetirizine in allergic rhinitis: a prospective, randomized, open-label, parallel-group study. Perspect Clin Res. 2025, 16:198-204. 10.4103\/picr.picr_206_24","journal-title":"Perspect Clin Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/466224-montelukast-and-bilastine-combination-therapy-in-allergic-rhinitis-a-narrative-review-of-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:28:59Z","timestamp":1785320939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/466224-montelukast-and-bilastine-combination-therapy-in-allergic-rhinitis-a-narrative-review-of-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":79,"URL":"https:\/\/doi.org\/10.7759\/cureus.113572","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}